Autoimmune Liver Disease Network for Kids (A-LiNK): Using Patient Data to Transform Care and Improve Outcomes for Children, Adolescents, and Young Adults With Autoimmune Liver Disease
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 800
- 试验地点
- 16
- 主要终点
- Baseline disease characteristics in the population
研究概览
简要总结
The Autoimmune Liver disease Network for Kids (A-LiNK) is a multi-institutional group with the mission to deliver the best care to kids with pediatric autoimmune liver disease (AILD).
This study will establish a shared clinical registry and a learning health network for the participating sites focusing on collecting and transmitting clinical measurement data, information about processes, and participation in an improvement collaborative.
Pediatric Autoimmune Hepatitis (AIH) and Primary Sclerosing Cholangitis (PSC), represent a spectrum of AILD which present unique diagnostic and therapeutic challenges.A lack of accepted guidelines for disease monitoring or symptom management results in wide treatment variation with liver transplants indicated in refractory, progressive disease.
The aims of A-LiNK are to:
1.) Create a learning health network focused on patient-centered outcomes research characterized by transparent sharing among centers, common priorities, and feasible plans for implementing new practices; 2) shift from traditional investigator-driven study to a patient and family-centered approach, and 3.) improve clinical outcomes and quality of life for pediatric AILD patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical diagnosis of autoimmune hepatitis (AIH)
- •Clinical diagnosis of primary sclerosing cholangitis (PSC)
- •Clinical diagnosis of autoimmune sclerosing cholangitis (ASC)
排除标准
- •History of liver transplant
研究组 & 干预措施
Children and adolescents with Autoimmune Liver Disease
Pediatric patients with a diagnosis of autoimmune hepatitis, or primary sclerosing cholangitis.
干预措施: No interventions (Other)
结局指标
主要结局
Baseline disease characteristics in the population
时间窗: 2034
Disease relapse and biochemical remission rates
时间窗: 2034
Biochemical remission = transaminases (ALT/AST) within the upper limit of normal for age
Complications of disease
时间窗: 2034
Including ascites, esophageal variceal bleeding, cholangitis, hepatic encephalopathy, listed for liver transplant, hepatocellular carcinoma, or cholangiocarcinoma
Side-effects of steroids
时间窗: 2034
Including hypertension, diabetes mellitus, low bone mineral density, glaucoma, cataract, overweight, obesity
Pediatric Quality of Life Inventory (PedsQL 4.0) Generic Core Scales Short Form 15
时间窗: 2034
Health-related quality of life
Racial and ethnic disparities
时间窗: 2034
次要结局
未报告次要终点
